[1] 马万瑞, 姜敏, 马乾凤, 等. 社区年龄>55岁人群非酒精性脂肪性肝病合并代谢综合征的现况分析. 中华高血压杂志, 2018, 26(6): 572-576. [2] Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, et al. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. J Fam Med Prim Care, 2019, 8(3): 923. [3] 杨小艳, 蹇贻, 钟玉全, 等. 非酒精性脂肪性肝病合并冠状动脉易损斑块患者的调查及预后分析. 中华内科杂志, 2020, 59(8): 623-628. [4] Wang B, Li F, Guo J, et al. Effects of liver function, insulin resistance and inflammatory factors on vascular endothelial dilation function and prognosis of coronary heart disease patients complicated with NAFLD. Exp Ther Med, 2019, 17(2): 1306-1311. [5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186. [6] Taylor R S, Taylor R J, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology, 2020, 158(6): 1611-1625. [7] Fadaei R, Poustchi H, Meshkani R, et al. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep, 2018, 8(1): 1-11. [8] 刘群, 栾桂萍, 高慧, 等. Tribbles同源蛋白1 rs2954029单核苷酸多态性与非酒精性脂肪性肝病及冠状动脉粥样硬化性心脏病的相关性分析. 临床肝胆病杂志, 2019, 35(6): 1330-1336. [9] 孟晓嵘, 代礼润, 余庆华, 等. 冠状动脉粥样硬化病变与非酒精性脂肪性肝病相关性分析. 中国医药, 2018, 13(12): 1766-1770. [10] Gonzalez-Cantero A, Teklu M, Sorokin A V, et al. Subclinical liver disease is associated with subclinical atherosclerosis in psoriasis: results from two observational studies. J Inves Dermatol, 2022, 142(1): 88-96. [11] Pirro M, Simental-Mendía L E, Bianconi V, et al. Effect of statin therapy on arterial wall inflammation based on 18F-FDG PET/CT: a systematic review and meta-analysis of interventional studies. J Clin Med, 2019, 8(1): 118. [12] Raynor W Y, Park P S U, Borja A J, et al. PET-BASED imaging with18F-FDG and 18F-NaF to assess inflammation and microcalcification in atherosclerosis and other vascular and thrombotic disorders. Diagnostics, 2021, 11(12): 2234. [13] Reijrink M, de Boer S A, te Velde-Keyzer C A, et al.18FFDG and 18F NaF as PET markers of systemic atherosclerosis progression: A longitudinal descriptive imaging study in patients with type 2 diabetes mellitus. J Nucl Cardiol, 2022, 29(4): 1702-1709. [14] Shao X, Chen Y, Chen Y, et al. Feasibility and application of trimetazidine in18F-FDG PET myocardial metabolic imaging of diabetic mellitus patients with severe coronary artery disease: A prospective, self-controlled study. J Nucl Cardiol, 2022, 29(5): 2497-2507. [15] Rane S, Thachathodiyl R, Palaniswamy S S, et al. Fluorodeoxyglucose-positron emission tomography (FDG-PET) of carotid arteries and non-alcoholic fatty liver disease (NAFLD): An analytical cross-sectional study from a teaching hospital, Kerala, South India. J Fam Mede Prim Care, 2022, 11(7): 3766-3770. [16] Hu L, Shao X, Qiu C, et al. Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by 18F-FDG PET/CT. Bmc Endocr Disord, 2020, 20(1): 1-9. [17] Alavi A, Werner T J, Raynor W, et al. Critical review of PET imaging for detection and characterization of the atherosclerotic plaques with emphasis on limitations of FDG-PET compared to NaF-PET in this setting. Am J Nucl Med Molec, 2021, 11(5): 337. [18] Kircher M, Tran-Gia J, Kemmer L, et al. Imaging inflammation in atherosclerosis with CXCR4-directed 68Ga-pentixafor PET/CT: correlation with 18F-FDG PET/CT. J Nucl Med, 2020, 61(5): 751-756. [19] Sarkar S, Corwin M T, Olson K A, et al. Pilot study to diagnose nonalcoholic steatohepatitis with dynamic18F-FDG PET. Am J Roentgenol, 2019, 212(3): 529-537. [20] Gao Y, Yuan L, Zeng J, et al. eIF6 is potential diagnostic and prognostic biomarker that associated with18F-FDG PET/CT features and immune signatures in esophageal carcinoma. J Transl Med, 2022, 20(1): 1-18. |